| URL: | https://dtp.cancer.gov/ncialmanac |
| Full name: | Developmental Therapeutics Program |
| Description: | The NCI ALMANAC study results may be navigated using four different methods. You may choose to view the data from a heat map containing the relative results from all drug pairs tested. You may also select a specific drug pair from drop-down lists. Alternatively, you may view the data from a heat map containing all results from a particular drug and optionally a modifier mechanism. Finally, you may generate a heat map showing how well each mechanism tested for a particular drug. For those wishing to analyze the entire dataset using their own tools, the data may be downloaded at https://wiki.nci.nih.gov/display/NCIDTPdata/NCI-ALMANAC. |
| Year founded: | 2017 |
| Last update: | |
| Version: | |
| Accessibility: |
Accessible
|
| Country/Region: | United States |
| Data type: | |
| Data object: | |
| Database category: | |
| Major species: | |
| Keywords: |
| University/Institution: | National Cancer Institute |
| Address: | Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland. |
| City: | Maryland |
| Province/State: | |
| Country/Region: | United States |
| Contact name (PI/Team): | Doroshow JH |
| Contact email (PI/Helpdesk): | doroshoj@mail.nih.gov |
|
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. [PMID: 28446463]
To date, over 100 small-molecule oncology drugs have been approved by the FDA. Because of the inherent heterogeneity of tumors, these small molecules are often administered in combination to prevent emergence of resistant cell subpopulations. Therefore, new combination strategies to overcome drug resistance in patients with advanced cancer are needed. In this study, we performed a systematic evaluation of the therapeutic activity of over 5,000 pairs of FDA-approved cancer drugs against a panel of 60 well-characterized human tumor cell lines (NCI-60) to uncover combinations with greater than additive growth-inhibitory activity. Screening results were compiled into a database, termed the NCI-ALMANAC (A Large Matrix of Anti-Neoplastic Agent Combinations), publicly available at https://dtp.cancer.gov/ncialmanac Subsequent in vivo experiments in mouse xenograft models of human cancer confirmed combinations with greater than single-agent efficacy. Concomitant detection of mechanistic biomarkers for these combinations in vivo supported the initiation of two phase I clinical trials at the NCI to evaluate clofarabine with bortezomib and nilotinib with paclitaxel in patients with advanced cancer. Consequently, the hypothesis-generating NCI-ALMANAC web-based resource has demonstrated value in identifying promising combinations of approved drugs with potent anticancer activity for further mechanistic study and translation to clinical trials. Cancer Res; 77(13); 3564-76. ©2017 AACR. |